Healthcare professional behaviour is shifting in ways that have direct commercial implications for companies operating in life sciences. The channels clinicians use, the formats they prefer and the speed at which conversations move are all evolving.
Clinicians are now engaging across a wider mix of digital environments, including specialist networks, professional social platforms and on-demand content channels. Traditional in-person engagement remains relevant, but it no longer dominates. As a result, companies that rely heavily on legacy outreach models face rising inefficiency. Capital allocation is increasingly dependent on understanding where attention is genuinely concentrated and how engagement translates into prescribing intent.
Peer-to-peer influence is playing a larger role in shaping perceptions of therapies. Online discussions allow clinicians to share experiences, question evidence and validate decisions in real time. This dynamic creates earlier visibility of sentiment trends and potential barriers to uptake. Companies equipped with tools to monitor and analyse these discussions can identify emerging risks or opportunities before they become evident in sales data.
At the same time, expectations around relevance have tightened. Clinicians increasingly filter out generic messaging in favour of information that aligns closely with their speciality and clinical priorities. This places pressure on companies to move from broad campaign models to targeted engagement strategies. Data infrastructure and analytics capability therefore become central assets rather than support functions.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
